Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONMD | PRESS-RELEASE | neutral | 4/10 | OneMedNet Corporation announced a multi-year resale agreement with Atropos Health to expand commercial distribution of i | Sep 22, 2026 |
| PALI | PRESS-RELEASE | bullish | 6/10 | Palisade Bio announced FDA clearance of its IND application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-C | Sep 22, 2026 |
| QNRX | PRESS-RELEASE | mixed | 5/10 | Quoin Pharmaceuticals announced FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, the first such designati | Sep 22, 2026 |
| PDSB | PRESS-RELEASE | bullish | 7/10 | PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology showing 39.3-month median overall survival in ICI-n | Sep 22, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 4/10 | Zenas BioPharma announced upcoming presentations of new data from the Phase 3 INDIGO open-label extension of obexelimab | Sep 22, 2026 |
| ELDN | PRESS-RELEASE | bullish | 7/10 | Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and presented posi | Sep 22, 2026 |
| MDWD | PRESS-RELEASE | bullish | 4/10 | MediWound received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formu | Sep 22, 2026 |
| CLDX | PRESS-RELEASE | bullish | 7/10 | Celldex reported positive Phase 3 topline results for barzolvolimab in chronic spontaneous urticaria (CSU). Both EMBARQ- | Sep 22, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions and Carbonium Core have mutually terminated their June 28, 2026 merger agreement, with each | Sep 21, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and RSUs to one new non-executive employee under its 2026 Inducemen | Sep 21, 2026 |
| BSEM | PRESS-RELEASE | neutral | 2/10 | BioStem Technologies has joined the Terminal1 platform for shareholder intelligence, investor communications, and digita | Sep 21, 2026 |
| PTCT | PRESS-RELEASE | bullish | 6/10 | PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Thera | Sep 21, 2026 |
| ANAB | PRESS-RELEASE | neutral | 5/10 | AnaptysBio reported Q2 2026 EPS of $0.07, a 50.5% miss vs consensus of $0.14, though collaboration revenue of $27.5M bea | Sep 21, 2026 |
| GRML | PRESS-RELEASE | neutral | 5/10 | Greenland Mines applied for a new 262 km² exploration license east of its Sarfartoq project in Greenland, expanding its | Sep 21, 2026 |
| HELP | PRESS-RELEASE | neutral | 4/10 | Helus Pharma presented four posters at Psych Congress 2026, including 12-month efficacy data from its Phase 1/2a study o | Sep 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix announces a transformational merger with ITM Isotope Technologies Munich SE for $1.65B upfront (cash-free/debt-fre | Sep 20, 2026 |
| CUE | PRESS-RELEASE | bullish | 7/10 | Cue Biopharma announced positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria (CSU), meeting the | Sep 20, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new real-world data at Psych Congress showing that UZEDY (risperidone) extended-release injectable suspen | Sep 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting in | Sep 18, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 2/10 | Zenas BioPharma granted inducement stock options and RSUs to new hires under Nasdaq Rule 5635(c)(4). The grants are rout | Sep 18, 2026 |
| BBIO | PRESS-RELEASE | neutral | 2/10 | BridgeBio Pharma granted 63,009 restricted stock units to 36 new employees as an inducement material to their employment | Sep 18, 2026 |
| GERN | PRESS-RELEASE | neutral | 2/10 | Geron Corporation granted inducement stock options for 821,250 shares to nine newly hired employees at $1.32 per share, | Sep 18, 2026 |
| AMRX | PRESS-RELEASE | bullish | 6/10 | Amneal Pharmaceuticals received FDA approval for its lanreotide injection (120 mg/0.5 mL), a generic version of Somatuli | Sep 18, 2026 |
| TCRT | PRESS-RELEASE | bearish | 5/10 | Alaunos Therapeutics announced a registered direct offering of ~767K shares (common + pre-funded warrants) at $1.46/shar | Sep 18, 2026 |
| SILO | PRESS-RELEASE | bullish | 5/10 | Silo Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering its lead asset SPC-15, an in | Sep 18, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 4/10 | TOMI Environmental Solutions reported Q2 2026 EPS of -$0.05, beating consensus of -$0.11 by 55.4%, but revenue was not d | Sep 18, 2026 |
| XRTX | PRESS-RELEASE | neutral | 4/10 | XORTX Therapeutics announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulatio | Sep 18, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings entered a payment agreement with Longevity Health Holdings converting its 5% net sales royalty from the El | Sep 18, 2026 |
| ABEO | PRESS-RELEASE | bullish | 6/10 | Abeona Therapeutics issued a press release congratulating Ultragenyx on FDA approval of FAYUVI (UX111) for MPS IIIA, a g | Sep 18, 2026 |
| BLSM | PRESS-RELEASE | neutral | 5/10 | BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), far exceeding the consensus estimate of $-0 | Sep 18, 2026 |